POZN ($10.91) short position on 4-22-10 & 4/5/10 This is shorted more today than it was two weeks ago. Shorties will get squeezed when Vimovo gets approved! Almost 7% of the float is shorted! It is now 13 on the squeeze list from 48 on April 5th. (Ignore Somaxon as I was comparing POZN to it on April 5th) Pozen is moving higher on low volume. We will see $11.00 today.$heff
POZN (11.21)…the only setback for Vimovo was on the clinical endpoints for the study in Dec 2008. The good news is they don't have to worry about finding out about it next week as The issue was resolved with the FDA because of the SPA. (FDA willingness to expedite communication). It seems the FDA is ready to move forward with Vimovo on April 30th. Most companies find out issues with their potential approval in an Advisory Panel or the FDA decision date. This was addressed a lot earlier in the process. Hence the importance of the SPA! Look at the correction with the FDA (about POZN reaching an agreement on the clinical endpoints) that I have in the 10Q underneath the 1st article. Look at the very last sentence. Great news moving forward! $heff
Market Data 
Markets 
AI
